Quemliclustat - Arcus Biosciences
Alternative Names: AB-680; Small molecule CD73 inhibitor - Arcus BiosciencesLatest Information Update: 11 Jul 2024
At a glance
- Originator Arcus Biosciences
- Developer Arcus Biosciences; Gilead Sciences; UCLAs Jonsson Comprehensive Cancer Center
- Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Fluorobenzenes; Phosphonic acids; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cholangiocarcinoma; Non-small cell lung cancer; Pancreatic cancer
- Phase I/II Colorectal cancer
- No development reported Cancer
- Discontinued Prostate cancer
Most Recent Events
- 08 Jul 2024 Taiho Pharmaceutical exercises option to in-license Quemliclustat from Arcus Biosciences
- 08 Jul 2024 Arcus Biosciences plans the phase III PRISM-1 trial for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in Japan, in 2024
- 02 Jun 2024 Efficacy and adverse events data from the phase Ib/II ARC-9 trial in Colorectal cancer released by Gilead Sciences